Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free CRDL Stock Alerts

Cardiol Therapeutics (CRDL) Competitors

Cardiol Therapeutics logo
C$1.53 -0.01 (-0.65%)
As of 07/3/2026 04:00 PM Eastern
Compare

CRDL vs. TEV, NOT, PYR, NVO, and FRX

Should you buy Cardiol Therapeutics stock or one of its competitors? MarketBeat compares Cardiol Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiol Therapeutics include Tervita (TEV), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), and Fennec Pharmaceuticals (FRX). These companies are all part of the "pharmaceutical products" industry.

How does Cardiol Therapeutics compare to Tervita?

Tervita (TSE:TEV) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Tervita has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tervita, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TervitaC$1.36B0.00-C$1.04M-C$0.01N/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A

In the previous week, Tervita's average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
Tervita Neutral
Cardiol Therapeutics Neutral

0.1% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tervita's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TervitaN/A N/A N/A
Cardiol Therapeutics N/A -229.16%-54.15%

Summary

Tervita beats Cardiol Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Noront Resources?

Noront Resources (CVE:NOT) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Noront Resources' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Noront ResourcesN/A N/A N/A
Cardiol Therapeutics N/A -229.16%-54.15%

In the previous week, Noront Resources' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
Noront Resources Neutral
Cardiol Therapeutics Neutral

0.1% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Noront Resources is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Noront ResourcesN/AN/AN/A-C$0.15N/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A

Summary

Noront Resources and Cardiol Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Cardiol Therapeutics compare to PyroGenesis Canada Inc. (PYR.V)?

PyroGenesis Canada Inc. (PYR.V) (CVE:PYR) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

PyroGenesis Canada Inc. (PYR.V)'s return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada Inc. (PYR.V)N/A N/A N/A
Cardiol Therapeutics N/A -229.16%-54.15%

In the previous week, PyroGenesis Canada Inc. (PYR.V)'s average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
PyroGenesis Canada Inc. (PYR.V) Neutral
Cardiol Therapeutics Neutral

0.1% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

PyroGenesis Canada Inc. (PYR.V) has higher revenue and earnings than Cardiol Therapeutics. PyroGenesis Canada Inc. (PYR.V) is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PyroGenesis Canada Inc. (PYR.V)C$6.01M100.97-C$3.94M-C$0.03N/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A

Summary

PyroGenesis Canada Inc. (PYR.V) beats Cardiol Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Novo Resources Corp. (NVO.V)?

Novo Resources Corp. (NVO.V) (CVE:NVO) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, Novo Resources Corp. (NVO.V) had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 1 mentions for Novo Resources Corp. (NVO.V) and 0 mentions for Cardiol Therapeutics. Novo Resources Corp. (NVO.V)'s average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company Overall Sentiment
Novo Resources Corp. (NVO.V) Neutral
Cardiol Therapeutics Neutral

Novo Resources Corp. (NVO.V)'s return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Resources Corp. (NVO.V)N/A N/A N/A
Cardiol Therapeutics N/A -229.16%-54.15%

0.1% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Novo Resources Corp. (NVO.V) is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Resources Corp. (NVO.V)N/AN/AN/A-C$0.11N/A
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A

Summary

Novo Resources Corp. (NVO.V) beats Cardiol Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Fennec Pharmaceuticals?

Cardiol Therapeutics (TSE:CRDL) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Cardiol Therapeutics has a beta of 0.37058, indicating that its share price is 63% less volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.522795, indicating that its share price is 252% more volatile than the broader market.

Fennec Pharmaceuticals has higher revenue and earnings than Cardiol Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.39N/A
Fennec PharmaceuticalsC$51.00M10.43-C$800.44K-C$0.29N/A

Cardiol Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Fennec Pharmaceuticals' return on equity of -58.09% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -229.16% -54.15%
Fennec Pharmaceuticals -17.22%-58.09%8.88%

0.1% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Fennec Pharmaceuticals shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

In the previous week, Cardiol Therapeutics' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cardiol Therapeutics Neutral
Fennec Pharmaceuticals Neutral

Summary

Fennec Pharmaceuticals beats Cardiol Therapeutics on 10 of the 12 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDL vs. The Competition

Export
MetricCardiol TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$176.37MC$6.60BC$7.18BC$13.07B
Dividend YieldN/A2.83%2.67%6.18%
P/E Ratio-3.925.1128.0236.51
Price / SalesN/A1,653.39532.5910.34
Price / Cash0.9810.1849.2682.29
Price / Book6.8910.8310.964.52
Net Income-C$42.93MC$20.27BC$3.57BC$299.09M
7 Day Performance1.32%1.30%2.12%1.85%
1 Month Performance-2.55%-1.17%5.25%1.71%
1 Year Performance-26.09%9.82%33.29%36.40%

Cardiol Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRDL
Cardiol Therapeutics
N/AC$1.53
-0.6%		N/A-26.1%C$176.37MN/AN/A20
TEV
Tervita
N/AN/AN/AN/AC$672.00MC$1.36BN/A36,800
NOT
Noront Resources
N/AC$1.10
-0.5%		N/A+0.0%C$612.18MN/AN/A101,700
PYR
PyroGenesis Canada Inc. (PYR.V)
N/AC$3.85
+11.0%		N/A+0.0%C$606.96MC$6.01MN/A90
NVO
Novo Resources Corp. (NVO.V)
N/AC$2.38
-0.4%		N/A+0.0%C$548.24MN/AN/A54,400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CRDL) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel